Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Stock Trading Up By 15.15%


Dallas, Texas 11/19/2013 (Financialstrend) – In Monday’s trading session, Synta Pharmaceuticals Corp. (NASDAQ:SNTA) rose by 15.15%. The shares opened at a price of $4.45, which touched the intraday high of $5.20 and headed to a close of $4.87. Around 6.08 million exchanged hands over the trading day and an average volume of 1.73 million shares were traded over a 30 day period. The 52-week low of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares is $3.70 and its 52-week high is $11.88. The company has a market capitalization of $336.39 million.

About the company

Synta Pharmaceuticals Corp. (NASDAQ:SNTA), the bio-pharma company was formed in March 2000. It concentrates on discovering, developing and in the commercialization of different small-molecule drugs that are utilized in the treatment of some severe medical conditions of patients who are suffering from inflammatory diseases or cancer.  As of 31st December 2011, Synta Pharmaceuticals Corp. (NASDAQ:SNTA) had 2 of its drug candidates in different clinical-trials for the treatment of different kinds of cancer.

In addition to this, the company also had several drug-candidates in the pre-clinical stage of development. Its drug candidates are discovered as well as developed internally. The company makes use of its chemical compound library as well as its integrated discovery engine. In the year that ended 31st December 2011, Synta Pharmaceuticals Corp. (NASDAQ:SNTA) initiated a Phase-2b/3 ganetespib clinical-trial as a mix with docetaxel for the treatment of non-small cell lung cancer. In 2011, the company also in concentrated on the elesclomol & calcium-release activated calcium-modulator programs.

Oncology Programs

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) had 2 clinical-stage programs & 1 preclinical-stage program in the oncology field, as of 31st December 2011. Its oncology programs include its elesclomol ganetespib and STA-9584 Ganetespib is the synthetic, small-molecule inhibitor of Hsp90. It is a chaperone protein that is necessary for the functioning of certain other proteins, e.g. tyrosine kinases that drives the growth,-proliferation & survival of numerous types of cancer.